Immunomodulatory effect of human adipose tissue‐derived adult stem cells: comparison with bone marrow mesenchymal stem cells

British Journal of Haematology - Tập 129 Số 1 - Trang 118-129 - 2005
Bénédicte Puissant-Lubrano1,2, Corinne Barreau3,4, Philippe Bourin5,3, C Clavel2,3, Jill Corre4, Christine Bousquet2, Christine Taureau2, Béatrice Cousin4, M. Abbal1,2, Patrick Laharrague6,4, Luc Pénicaud4, Louis Casteilla4, Antoine Blancher1,2
1Laboratoire d'Immunogénétique Moléculaire, Faculté de médecine Toulouse-Rangueil, Bâtiment A2, 133 Route de Narbonne, Toulouse Cedex 04
2Laboratoire d'Immunologie, Hôpital Rangueil, 1 avenue Jean Poulhès, TSA 50032, Toulouse cedex 9
3These authors contributed equally to this study
4UMR-CNRS 5018, IFR31, Hôpital Rangueil, 1 avenue Jean Poulhès, TSA 50032, Toulouse cedex 9
5Service de thérapie cellulaire Etablissement Français du Sang, Pyrénées Méditerranée, Site de Toulouse
6Laboratoire d'Hématologie, Hôpital Rangueil, 1 avenue Jean Poulhès, TSA 50032, Toulouse cedex 9, France

Tóm tắt

Summary

Like mesenchymal stem cells from bone marrow (BM‐MSCs), adipose tissue‐derived adult stem cells (ADAS cells) can differentiate into several lineages and present therapeutical potential for repairing damaged tissues. The use of allogenic stem cells can enlarge their therapeutical interest, provided that the grafted cells could be tolerated. We investigate here, for the first time, the immunosuppressive properties of ADAS cells compared with the well‐characterized immunosuppressive properties of BM‐MSCs. ADAS cells did not provoke in vitro alloreactivity of incompatible lymphocytes and, moreover, suppressed mixed lymphocyte reaction (MLR) and lymphocyte proliferative response to mitogens. The impairment of inhibition when ADAS cells and BM‐MSCs were separated from lymphocytes by a permeable membrane suggests that cell contact is required for a full inhibitory effect. Hepatocyte growth factor is secreted by both stem cells but, similar to interleukin‐10 and transforming growth factor‐β (TGF‐β), the levels of which were undetectable in supernatants of MLR inhibited by ADAS cells or BM‐MSCs, it did not seem implicated in the stem cell suppressive effect. These findings support that ADAS cells share immunosuppressive properties with BM‐MSCs. Therefore, ADAS cell‐based reconstructive therapy could employ allogenic cells and because of their immunosuppressive properties, ADAS cells could be an alternative source to BM‐MSCs to treat allogenic conflicts.

Từ khóa


Tài liệu tham khảo

10.1182/blood-2004-04-1559

10.1080/14653240310004539

10.3727/000000004773301771

10.1016/S0301-472X(01)00769-X

10.1002/jgm.452

10.1016/S0006-291X(03)00061-5

10.1159/000071150

10.1016/S0301-472X(00)00482-3

10.1182/blood-2002-06-1830

10.1182/blood.V99.10.3838

10.1182/blood-2003-04-1193

10.1006/bbrc.2001.6270

10.1016/j.biocel.2003.10.018

Frassoni F., 2002, Expanded mesenchymal stem cells (MSC) co‐infused with HLA identical hemopoietic stem cell transplants, reduce acute and chronic graft versus host disease: a matched paired analysis. 28th EBMT annual meeting, 18th meeting of the EBMT Nurses Group and 1st meeting of the EBMT Data Management Group. Montreux, Switzerland, 2002, Bone Marrow Transplantation, 29, S1

10.1080/14653240310003026

10.1016/S0070-2153(03)58005-X

10.1056/NEJM200107123450203

10.1002/jcp.1138

10.1089/107632704323061735

10.1182/blood.V97.5.1227

10.1038/sj.gt.3302019

10.1200/JCO.2000.18.2.307

10.1182/blood-2002-07-2104

10.1096/fasebj.12.9.747

Lazarus H.M., 1995, Ex vivo expansion and subsequent infusion of human bone marrow‐derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use, Bone Marrow Transplantation, 16, 557

Lazarus H., 2000, Role of mesenchymal stem cells (msc) in allogenic transplantation: early phase 1 clinical results, Blood, 96, 392a

10.1046/j.1365-3083.2003.01176.x

10.1111/j.0300-9475.2004.01483.x

10.1046/j.1365-2141.2002.03767.x

10.1161/01.CIR.0000135466.16823.D0

10.1089/10430340360464714

10.1073/pnas.76.10.5138

10.1002/jor.1100090504

10.1161/01.RES.0000109792.43271.47

10.1161/01.CIR.0000114522.38265.61

10.1016/S0006-291X(02)00469-2

10.1097/01.TP.0000045055.63901.A9

10.1097/01.TP.0000048488.35010.95

10.1091/mbc.e02-02-0105

Thông tin
Thông tin xuất bản

British Journal of Haematology

Tập 129 Số 1

118-129

Thông tin tác giả